Chimeric antigen receptor-T(CAR-T)cell therapy has revolutionized cancer treatment,yet its application to autoimmune diseases remains in its infancy.In 2024,Professor Huji Xu and his colleagues achieved a groundbreaki...Chimeric antigen receptor-T(CAR-T)cell therapy has revolutionized cancer treatment,yet its application to autoimmune diseases remains in its infancy.In 2024,Professor Huji Xu and his colleagues achieved a groundbreaking milestone in allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis.In this dialogue,Professor Xu elaborated on the rationale and development of allogeneic CAR-T therapy as a cost-effective,scalable alternative to autologous approaches.By utilizing multiplex genome-edited CD19-targeted CAR-T cells derived from healthy donors,his team aims to address critical challenges in manufacturing,accessibility,and long-term efficacy.Professor Xu also discussed strategies for cost reduction,regulatory hurdles,and the broader implications for immunotherapy.Drawing on his extensive experience,he envisions allogeneic CAR-T therapy emerging as a transformative treatment for autoimmune diseases,with the potential to achieve widespread accessibility and profound clinical impact.展开更多
文摘Chimeric antigen receptor-T(CAR-T)cell therapy has revolutionized cancer treatment,yet its application to autoimmune diseases remains in its infancy.In 2024,Professor Huji Xu and his colleagues achieved a groundbreaking milestone in allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis.In this dialogue,Professor Xu elaborated on the rationale and development of allogeneic CAR-T therapy as a cost-effective,scalable alternative to autologous approaches.By utilizing multiplex genome-edited CD19-targeted CAR-T cells derived from healthy donors,his team aims to address critical challenges in manufacturing,accessibility,and long-term efficacy.Professor Xu also discussed strategies for cost reduction,regulatory hurdles,and the broader implications for immunotherapy.Drawing on his extensive experience,he envisions allogeneic CAR-T therapy emerging as a transformative treatment for autoimmune diseases,with the potential to achieve widespread accessibility and profound clinical impact.
